First-line endocrine treatment with leuprorelinacetate-depot in pre- and perimenopausal patients with metastatic breast cancer;Endokrine primartherapie des pra- bzw. perimenopausalen metastasierten mammakarzinoms mit leuprorelinacetat-depot

Zentralblatt fur Gynakologie

Volumn 120, Issue 6, 1998, Pages 284-292

  Untch, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

GnRH Analoges; Leuprorelinacetate; Metastatic breast cancer

Indexed keywords

GONADORELIN AGONIST; GONADOTROPIN; LEUPRORELIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; LUTEINIZING HORMONE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; SWEATING; BLOOD; BREAST TUMOR; CANCER STAGING; DELAYED RELEASE FORMULATION; DISEASE COURSE; MIDDLE AGED; MORTALITY; NEOPLASM; PATHOLOGY; PREMENOPAUSE; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; ESTRADIOL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUPROLIDE; LUTEINIZING HORMONE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PREMENOPAUSE; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0031614829     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Carel JC, Lahlou N, Guazzarotti L, Joubert-Collin M, Roger M, Colle M, The French Leuprorelin Trial Group and Jean Louis Chaussain: Treatment of central precocious puberty with depot leuprorelin. Eur J Endocrinol 132 (1995) 699-704
2. Debruyne FM, Denis L, Lunglmayr G, Mahler C, Newling DW, Richards R, Robinson MK, Smith PH, Weil EH, Whelan P: Long term therapy with a depot luteinizing hormonereleasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Urol 140 (1988) 775-777
3. Dowsett M, Jacobs S, Aherne J, Smith IE: Clinical and endocrine effects of Leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer. Clin Therapeutics 14 (1992) Suppl., 97-103
4. Fornander T, Rutqvist LE, Glas U: Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen. CancerTreat Rep 71 (1987) 685-688
5. Goldhirsch A, Gelber RD: Endocrine Therapies of Breast Cancer. Semin Oncol 23 (1996) 494-505
6. Harvey HA, Lipton A, Max DT, Pearlman HG, Diaz-Perches R, de la Garza J: Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J Clin Oncol 3 (1985) 1068-1072
7. Hayes DF, Henderson IC, Shapiro CL: Treatment of Metastatic Breast Cancer: Present and Future Prospects. Semin Oncol 22 (1995) Suppl. 5, 5-21
8. Henderson IC: Endocrine therapy of metastatic breast cancer. In: Breast Diseases. Eds.: Harris JR. Hellmann S, Henderson IC et al. Philadelphia: Lippincott 1991, 559-603
9. Hoffmann G, Pollow K, Schaffrath M, Pollow B, Weickel W, Kreienberg R, Strittmatter HJ, Fahl K: Diskrepanzen im Sexualsteroidrezeptorbesatz zwischen Primärtumor und Metastase beim Mammakarzinom. Tumordias Therapie 17 (1996) 97-105
10. Kardinal CG, Perry MC, Korzun AH: Responses to chemotherapy orchemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB study 8081. Cancer 61 (1988) 415-419
11. Kaufmann M, Jonat W, Schachner-Wunschmann E, Bastert G, Maass H: The depot GnRH analogue Goserelin in the treatment of premenopausal patients with metastatic breast cancer: A 5 year experience and further endocrine therapies. Oncologie 22 (1991) 22-30
12. Klijn JGM, Seynaeve C, Beex L, Mauriac L, Zijl van J, Veyret C, Wildiers J, Jassem J, Burghouts J, Becquart M, Namer M, Piccart M, Garcia-Conde J, Mignolet F, Hoctin-Boes G, members, of the EORTC Breast Cancer Coop. Group Dr. Daniel den Hoed Kliniek, Erasmus University, Rotterdam. Eur J Cancer 32 (1996) Suppl. 2, 49
13. Loprinzi CL, Tormey DC, Rasmusssen P, Falkson G, Davis TE, Falkson HC, Chang AY, Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol 4 (1986) 46
14. Mettler L, Mayer-Eichberger D, Kienle E, Lipka K: Leuprorelinacetat-Depot zur Behandlung des Uterus myomatosus. Fertilität 9 (1993) 167-174
15. Muss HB, Smith LR, Cooper MR: Tamoxifen rechalenge: Response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer. J Clin Oncol 5 (1987) 1556-1558
16. Nissen-Meyer R, Kjellgren K, Mansson B: Adjuvant Chemotherapy in breast cancer. Rec Results Cancer Res 80 (1982) 142
17. Possinger K, Wagner H, Langecker P, Müller A, Wilmanns W: Prognosis-Adapted systemic therapy in patients with metastasized breast cancer. Proc Am Assoc Cancer Res (1988) 786, 198
18. Possinger K, Wilmanns W: Palliative Therapieführung zur Hemmung der Tumorprogression bei Patientinnen mit metastasierten Mammakarzinomen. Internist 34 (1993) 340-350
19. Possinger K, Flath B, Grunewald R: Mammakarzinom Therapie bei Metastasierung. TW Gynäkologie 9 (1996) 319-328
20. Schindler AE, Bühler K, Gerhard I, Wiedemann R, Kimmig R, Schüssler B, Kranzfelder D, Mall-Häfeli M, Meinen K, Hoffmann G, Kienle E: Behandlung der Endometriose mit dem GnRH-Agonisten Leuprorelinacetat-Depot (Enantone-Gyn Monats-Depot): Eine multizentrische Studie. Zentralb] Gynakol 116 (1994) 679-686
21. Schnürch H-G: Endokrine Therapien beim Mammakarzinom. Gynäkologe 26 (1993) 107-117
22. Stauder H, Robben-Bathe P, Meyer SM, Terrahe IM: Medikamentöse Therapie des metastasierten Mammakarzinoms. Klinikarzt 4/25 (1996) 119-122
23. Taylor CW, Green S, Dalton WS, martino S, Ingle JN, Robert NJ, Rector DJ, Osborne CK: A multicenter randomized trial of Zoladex versus surgical ovariectomy in premenopausal patients with receptor positive metastatic breast cancer. Breast Cancer Res Treat 37 (1996) Suppl., 37
24. Untch M, Fuchs W, Kreienberg R: Clinical efficacy of leuprorelin acetate monthly depot in premenopuasal patients with metastatic breast cancer. Oncol Reports 4 (1997) 717-721
25. Watanabe T, Adache I, Taguchi T, Koyama H, Yayoi K, Wada T, Takasuka Y, sonoo H, Morimoto K, Tominage T, Abe R, Enomote K, Miura S, Wada H, Yamantodani A with members of the TAP-144-SR Breast Cancer Study Group, Tokyo Japan 104: Phase II trial of TAP-144-SR (leuprorelin sustained release formulation) in premenopausal patients with metastatic breast cancer (MBC). Breast Cancer Res Treatm 37 (1996) 233
26. Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ: Randomized open labelled comparative study and tolerabilhy of leuprorelin acetate IM and 3M depot in patients with advanced prostatic cancer. Eur Urol 30 (1996) Suppl. I, 7-14
27. Wenderlein JM: GnRH-Analoga statt Ovarektomie! TW Gynäkologie 8 (1995) 275-278
28. Yamazaki I, Okada H: A radioimmunoassay for a highly active luteinising hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin. Endocr J 27 (1980) 593-605
29. Valagussa P, Tancini G, Bonadonna G: Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58 (1986) 1411-1417